4.7 Article

Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia

期刊

LEUKEMIA
卷 37, 期 8, 页码 1649-1659

出版社

SPRINGERNATURE
DOI: 10.1038/s41375-023-01963-4

关键词

-

向作者/读者索取更多资源

Despite the approval of several drugs for AML, resistance to cytarabine is common. RNA splicing and phosphorylation of SR proteins were found to be altered during cytarabine resistance. Inhibition of RNA splicing, alone or in combination with venetoclax, could be a potential treatment strategy for AML.
Despite the approval of several drugs for AML, cytarabine is still widely used as a therapeutic approach. However, 85% of patients show resistance and only 10% overcome the disease. Using RNA-seq and phosphoproteomics, we show that RNA splicing and serine-arginine-rich (SR) proteins phosphorylation were altered during cytarabine resistance. Moreover, phosphorylation of SR proteins at diagnosis were significantly lower in responder than non-responder patients, pointing to their utility to predict response. These changes correlated with altered transcriptomic profiles of SR protein target genes. Notably, splicing inhibitors were therapeutically effective in treating sensitive and resistant AML cells as monotherapy or combination with other approved drugs. H3B-8800 and venetoclax combination showed the best efficacy in vitro, demonstrating synergistic effects in patient samples and no toxicity in healthy hematopoietic progenitors. Our results establish that RNA splicing inhibition, alone or combined with venetoclax, could be useful for the treatment of newly diagnosed or relapsed/refractory AML.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据